4-nitrobenzylthioinosine has been researched along with dizocilpine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bartoccini, F; Carminati, P; Castorina, M; Di Cesare, MA; Di Serio, S; Gallo, G; Ghirardi, O; Giorgi, F; Giorgi, L; Minetti, P; Piersanti, G; Tarzia, G; Tinti, MO | 1 |
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
2 other study(ies) available for 4-nitrobenzylthioinosine and dizocilpine
Article | Year |
---|---|
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Cell Line; Cricetinae; Cricetulus; Drug Design; Humans; Imidazoles; Male; Models, Molecular; Motor Activity; Purines; Radioligand Assay; Rats; Rats, Inbred F344; Structure-Activity Relationship; Triazoles | 2005 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |